Do immune check inhibitors have a role in the treatment of higher-risk MDS? [MDS Professional Report]

Chien Aza – Pembro - BJH The combination of azacitidine and pembrolizumab may be a potential effective regimen for patients with higher-risk MDS and may lead to the introduction of an important class of medications into MDS practice Nazha, Prog model – JCO A personalized prediction model, based on clinical and genomic data, outperformed established prognostic models in MDS. The use of digital tools allow us to manage big data taken from large numbers of patients and include them in the newly developed diagnostic and prognostic models. Keundgen , t-MDS- Leukemia Therapy-related MDS should be classified as a separate entity distinct from other WHO-classified t-myeloid neoplasms, which would enhance treatment decisions and facilitate the inclusion of t-MDS patients into clinical studies. Strapatsas, PLT, Ann Hem The authors re-confirm the importance of PLT count as a prognostic factor in MDS, both at presentation and during the disease course. Bleeding is a leading (3rd ) cause of death in these patients.

You can listen to Do immune check inhibitors have a role in the treatment of higher-risk MDS? [MDS Professional Report] online on Radio and Podcast. Open the player on this page to stream the available audio.

Do immune check inhibitors have a role in the treatment of higher-risk MDS? [MDS Professional Report] is an episode from MDS Professional Report by PI Media.

This episode is 23:44 long.

This episode was published on Sep 22, 2021.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from MDS Professional Report when more episodes are available from the podcast feed.